A Novel Substituted Guanidine with High Activity in vitro against Rhinoviruses

THE number and diversity of the viruses which infect the upper respiratory tract, and cause the common cold, virtually preclude the control of this disease by conventional vaccines. From this, apart from symptomatic therapy, the only hope for effective treatment of this most prevalent of diseases is...

Descripción completa

Detalles Bibliográficos
Autores principales: BUCKNALL, R. A., SWALLOW, D. L., MOORES, H., HARRAD, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 1973
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086493/
https://www.ncbi.nlm.nih.gov/pubmed/4357165
http://dx.doi.org/10.1038/246144a0
_version_ 1783509132488212480
author BUCKNALL, R. A.
SWALLOW, D. L.
MOORES, H.
HARRAD, J.
author_facet BUCKNALL, R. A.
SWALLOW, D. L.
MOORES, H.
HARRAD, J.
author_sort BUCKNALL, R. A.
collection PubMed
description THE number and diversity of the viruses which infect the upper respiratory tract, and cause the common cold, virtually preclude the control of this disease by conventional vaccines. From this, apart from symptomatic therapy, the only hope for effective treatment of this most prevalent of diseases is in the development of broad spectrum antiviral drugs. We have developed a substituted guanidine, ICI 65,709 (ref. 1) (Fig. 1) which has good activity in vitro against all twenty-five rhinovirus serotypes tested in human embryonic lung cells, and also against certain other picornaviruses.
format Online
Article
Text
id pubmed-7086493
institution National Center for Biotechnology Information
language English
publishDate 1973
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70864932020-03-23 A Novel Substituted Guanidine with High Activity in vitro against Rhinoviruses BUCKNALL, R. A. SWALLOW, D. L. MOORES, H. HARRAD, J. Nature Article THE number and diversity of the viruses which infect the upper respiratory tract, and cause the common cold, virtually preclude the control of this disease by conventional vaccines. From this, apart from symptomatic therapy, the only hope for effective treatment of this most prevalent of diseases is in the development of broad spectrum antiviral drugs. We have developed a substituted guanidine, ICI 65,709 (ref. 1) (Fig. 1) which has good activity in vitro against all twenty-five rhinovirus serotypes tested in human embryonic lung cells, and also against certain other picornaviruses. Nature Publishing Group UK 1973 /pmc/articles/PMC7086493/ /pubmed/4357165 http://dx.doi.org/10.1038/246144a0 Text en © Nature Publishing Group 1973 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
BUCKNALL, R. A.
SWALLOW, D. L.
MOORES, H.
HARRAD, J.
A Novel Substituted Guanidine with High Activity in vitro against Rhinoviruses
title A Novel Substituted Guanidine with High Activity in vitro against Rhinoviruses
title_full A Novel Substituted Guanidine with High Activity in vitro against Rhinoviruses
title_fullStr A Novel Substituted Guanidine with High Activity in vitro against Rhinoviruses
title_full_unstemmed A Novel Substituted Guanidine with High Activity in vitro against Rhinoviruses
title_short A Novel Substituted Guanidine with High Activity in vitro against Rhinoviruses
title_sort novel substituted guanidine with high activity in vitro against rhinoviruses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086493/
https://www.ncbi.nlm.nih.gov/pubmed/4357165
http://dx.doi.org/10.1038/246144a0
work_keys_str_mv AT bucknallra anovelsubstitutedguanidinewithhighactivityinvitroagainstrhinoviruses
AT swallowdl anovelsubstitutedguanidinewithhighactivityinvitroagainstrhinoviruses
AT mooresh anovelsubstitutedguanidinewithhighactivityinvitroagainstrhinoviruses
AT harradj anovelsubstitutedguanidinewithhighactivityinvitroagainstrhinoviruses
AT bucknallra novelsubstitutedguanidinewithhighactivityinvitroagainstrhinoviruses
AT swallowdl novelsubstitutedguanidinewithhighactivityinvitroagainstrhinoviruses
AT mooresh novelsubstitutedguanidinewithhighactivityinvitroagainstrhinoviruses
AT harradj novelsubstitutedguanidinewithhighactivityinvitroagainstrhinoviruses

Ejemplares similares